Drugs, Growth Factors and Active Molecules for Tissue Engineering and Regenerative Medicine

Dear Colleagues,

Tissue engineering strategies based on active compounds represent promising approaches to the regeneration of damaged or diseased tissues and organs. In this context, regenerative medicine holds immense potential for both the treatment of diseases and the improvement of quality of life. This Special Issue, titled “Drugs, Growth Factors and Active Molecules for Tissue Engineering and Regenerative Medicine”, is dedicated to examining the effects of drugs, growth factors, and bioactive molecules with the aim of optimizing progress in tissue engineering and regenerative medicine.

This collection aims to disseminate innovative research, methodologies, and advances at the interface of pharmaceuticals, biomaterials, and cells, with particular emphasis on cutting-edge aspects of drug-loaded carriers, bioactive scaffold formulations, and in vivo evaluations.

The convergence of pharmaceuticals and regenerative medicine offers significant potential to tackle complex healthcare challenges. With this initiative, we aim to foster transformative progress, establishing a foundation for innovative pharmaceutical strategies that enhance the regenerative potential of drugs.

Dr. Natasha Maurmann
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.